We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Research Drugs Should Be Exempt From FDA Border Processes, Industry Says
Research Drugs Should Be Exempt From FDA Border Processes, Industry Says
August 27, 2013
Imports of drugs intended for research should be exempt from new FDA border processes implemented under the FDA Safety and Innovation Act (FDASIA), industry stakeholders say.